|
|
|
|
| LEADER |
00000cam a2200000Ii 4500 |
| 001 |
11706035 |
| 006 |
m o d |
| 007 |
cr cnu|||unuuu |
| 008 |
180917s2018 si ob 000 0 eng d |
| 005 |
20240509213210.7 |
| 015 |
|
|
|a GBB8M1798
|2 bnb
|
| 016 |
7 |
|
|a 019056790
|2 Uk
|
| 019 |
|
|
|a 1053610394
|a 1108752619
|
| 020 |
|
|
|a 9789811304965
|q (electronic bk.)
|
| 020 |
|
|
|a 9811304963
|q (electronic bk.)
|
| 020 |
|
|
|z 9789811304958
|
| 020 |
|
|
|z 9811304955
|
| 035 |
|
|
|a (OCoLC)1052613030
|z (OCoLC)1053610394
|z (OCoLC)1108752619
|
| 035 |
|
9 |
|a (OCLCCM-CC)1052613030
|
| 037 |
|
|
|a com.springer.onix.9789811304965
|b Springer Nature
|
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d GW5XE
|d EBLCP
|d YDX
|d NLE
|d OCLCF
|d UAB
|d OTZ
|d OH1
|d OCLCO
|d OCLCA
|d LVT
|d OCLCA
|d MERER
|d OCLCO
|d UKMGB
|d OCLCA
|d U3W
|d OCLCA
|d CAUOI
|d OCLCO
|d COO
|d OCLCO
|d CASUM
|d OCLCQ
|d OCLCA
|d OCLCQ
|d OCLCA
|d OCLCQ
|
| 049 |
|
|
|a MAIN
|
| 050 |
|
4 |
|a RM282.M65
|b D48 2018
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 245 |
0 |
0 |
|a Development of antibody-based therapeutics :
|b translational considerations & challenges /
|c Mohammad A. Tabrizi, Gadi G. Bornstein, Scott L. Klakamp, editors.
|
| 250 |
|
|
|a Second edition.
|
| 264 |
|
1 |
|a Singapore :
|b Adis,
|c [2018]
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 504 |
|
|
|a Includes bibliographical references.
|
| 588 |
|
|
|a Online resource; title from PDF title page (EBSCO, viewed September 20, 2018).
|
| 505 |
0 |
|
|a Introduction -- Translational considerations and challenges : an overview -- Considerations for construct and affinity design goals -- Epitope characterization and isotype selection -- Biophysical considerations for development of antibody-based therapeutics -- Novel technologies for generation of bispecific constructs -- Stimulus-response mechanisms : an overview -- Evaluation of tumor growth inhibition in preclinical tumor models : a quantitative approach -- Application of proof-of-mechanism biomarkers (POM) in design and development of biologics modalities -- Antibody drug conjugates : translational considerations -- Application of PK-PD modeling and simulation approaches for immuno-oncology drugs -- Translational biomarkers : application in the clinical development of combination therapies -- Correction to : considerations for construct and affinity design goals.
|
| 520 |
|
|
|a This book examines vital considerations in designing effective translational strategies in the development of antibody-based therapeutics, including the relationship between the 'unit dose' and 'unit effect' with respect to beneficial and deleterious effects.
|
| 650 |
|
0 |
|a Monoclonal antibodies
|x Therapeutic use.
|
| 650 |
1 |
2 |
|a Antibodies, Monoclonal
|x pharmacology.
|
| 650 |
2 |
2 |
|a Antibodies, Monoclonal
|x therapeutic use.
|
| 650 |
2 |
2 |
|a Antigens
|x immunology.
|
| 650 |
2 |
2 |
|a Drug Discovery.
|
| 650 |
2 |
2 |
|a Translational Medical Research.
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Pharmacology.
|2 bicssc
|
| 650 |
|
7 |
|a Biochemistry.
|2 bicssc
|
| 650 |
|
7 |
|a Pharmacy
|x dispensing.
|2 bicssc
|
| 650 |
|
7 |
|a Monoclonal antibodies
|x Therapeutic use.
|2 fast
|0 (OCoLC)fst01025554
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Tabrizi, Mohammad A.,
|e editor.
|
| 700 |
1 |
|
|a Bornstein, Gadi G.,
|e editor.
|
| 700 |
1 |
|
|a Klakamp, Scott L.,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Development of antibody-based therapeutics.
|b Second edition.
|d Singapore : Adis, [2018]
|z 9811304955
|z 9789811304958
|w (OCoLC)1030909638
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a oclccm
|
| 999 |
f |
f |
|i 6b660f8d-1460-54c3-bec8-d7f206a2b839
|s e5398691-9adc-5083-b405-ad7dc23dd1a1
|
| 928 |
|
|
|t Library of Congress classification
|a RM282.M65 D48 2018
|l Online
|c UC-FullText
|u https://link.springer.com/10.1007/978-981-13-0496-5
|z Springer Nature
|g ebooks
|i 12556848
|
